Ultivue

26 articles about Ultivue

• OMAPiX Announces Strategic Partnerships with Leading Spatial Biology Platform Providers to Accelerate Life Science Research and Drug Development

  6/26/2023

  OMAPiX announced strategic partnerships with Vizgen, Inc., Resolve Biosciences, and Ultivue, Inc.

• Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

  9/29/2022

  Ultivue, Inc. and, the Translational Research Unit platform of University of Bern announce a collaborative agreement to promote multiplexed immunofluorescence assays and the use of next generation TMAs to unlock spatial analysis in scientific research and improve the quality of TMAs integrated in clinical and translational research.

• Ultivue Announces AI Partner Ecosystem to Accelerate Analysis of Multiplex Immunofluorescence Image Data in Translational Medicine

  5/12/2022

  Ultivue, Inc., an industry leader in multiplexing assays and analytics solutions for tissue biomarker studies, announced multiple collaborations for AI-powered spatial phenomics solutions for translational research groups and Biopharma.

• Ultivue Announces Multiple Events for Multiplex Immunofluorescence and Image Analysis Technology in Immuno-Oncology Research at AACR 2022

  4/6/2022

  Ultivue, Inc. today announced that data from its FlexVUE™ formatting for panel design and its newest mouse panel offering for multiplex immunofluorescence (mIF) and spatially resolved biomarker analysis will be presented at the upcoming American Association for Cancer Research (AACR),

• Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research

  3/29/2022

  Keen Eye and Ultivue announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.

• Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine

  3/15/2022

  Ultivue, Inc. and Sirona Dx announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and Biopharma.

• Ultivue Announces Co-Marketing Agreement with Aignostics for Unique Spatial AI-Powered Imaging Solutions for Translational Medicine

  3/9/2022

  Ultivue, Inc. and Aignostics GmbH announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.

• Ultivue Announces New Executive Team Member - Nov 02, 2021

  11/2/2021

  Ultivue announces the addition of Steve Pemberton in the role of SVP Commercial Development, as the company adds to its growing executive team.

• Ultivue Announces New Independent Board Members

  8/19/2021

  Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation.

• Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision MedicineObjective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development

  8/5/2021

  Fluidigm Corporation today announced a co-marketing agreement with Ultivue, Inc., under which the companies will offer a comprehensive portfolio of solutions for biomarker discovery and drug development.

• Ultivue Announces New Executive Team Member

  4/22/2021

  Ultivue announces the addition of Richard C. Malabre, CPA in the role of Chief Financial Officer, as the company adds to its growing executive team.

• Ultivue Announces New Executive Team Members in Research and Corporate Development

  2/17/2021

  Ultivue announces the addition of new executive team members in order to help strengthen its position as a leading assay development solutions provider for multiplex biomarker analysis for tissue phenotyping . Mike Sismour, PhD has joined Ultivue in the role of Vice President, Research, and Mark Rees, PhD has joined as Vice President, Corporate Development.

• Ultivue to Participate in Cowen’s 41st Annual Health Care Conference

  2/11/2021

  Ultivue to Participate in Cowen’s 41 st Annual Health Care Conference

• Ultivue and Indivumed Partner for Research and Drug Development in Personalized Oncology

  11/18/2020

  Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research and drug development in the area of personalized oncology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005281/en/ The deal links Indivumed’s vast array of standardized and fully c

• Ultivue Raises $22 Million in Series C Funding

  6/27/2019

  Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by new investor Northpond Ventures and fueled by existing investors including ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital, and Applied Ventures.

• Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis

  3/29/2019

  Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer in artificial intelligence (AI) based image analysis, today announced a collaboration to expand Definiens standardized IO-Panel capabilities to IF.

• Ultivue releases breakthrough innovations for multiplex IHC: 16-marker whole-slide visualization and high marker co-localization in FFPE tissue

  3/28/2019

  Ultivue unveiled the expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology through comprehensive visualization of a whole slide 16-marker multiplex assay in tissue.

• Ultivue Expands Global Presence with Opening of European Subsidiary, Ultivue EMEA Srl

  2/21/2019

  Mr. Pirovano is an international executive with significant experience managing European Diagnostics and Life Science operations and will be responsible for managing the new subsidiary, Ultivue EMEA Srl, located in Milan, Italy.

• Ultivue to Release a Breakthrough 9-Color Multiplex IHC Panel Achieving Same Day Sample-to-Analysis at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018

  11/7/2018

  Ultivue, a life science company developing reagent-driven strategies for high-performance biological imaging in situ, today announced expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology.

• Ultivue Expands Its Portfolio of Digital Quantitative Pathology Services with a Suite of Image Analysis Capabilities Powered by Indica Labs HALO™, HALO LINK™ and Amazon Web Services

  9/13/2018

  Ultivue has announced today the expansion of its menu of Digital Quantitative Pathology Services with a complete suite of Image Analysis capabilities.